Literature DB >> 25200950

CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.

Sukhbir Kaur1, Tiffany Chang1, Satya P Singh2, Langston Lim3, Poonam Mannan3, Susan H Garfield3, Michael L Pendrak1, David R Soto-Pantoja1, Avi Z Rosenberg1, Shelly Jin1, David D Roberts4.   

Abstract

Thrombospondin-1 (TSP1) inhibits angiogenesis, in part, by interacting with the ubiquitous cell-surface receptor CD47. In endothelial cells, CD47 interacts directly with vascular endothelial growth factor receptor (VEGFR)-2, and TSP1 inhibits VEGFR2 phosphorylation and signaling by disrupting this association. We show that CD47 similarly associates with and regulates VEGFR2 in T cells. TSP1 inhibits phosphorylation of VEGFR2 and its downstream target Src in wild type but not in CD47-deficient human Jurkat and primary murine T cells. VEGFR2 signaling inhibits proliferation and TCR signaling in wild type T cells. However, ligation of CD47 by TSP1 or loss of CD47 expression reverses some inhibitory effects of VEGF on proliferation and T cell activation. We further found that VEGF and VEGFR2 expression are upregulated in CD47-deficient murine CD4(+) and human Jurkat T cells, and the resulting autocrine VEGFR2 signaling enhances proliferation and some TCR responses in the absence of CD47. Thus, CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of VEGF by T cells contributes to this regulation. This provides a mechanism to understand the context-dependent effects of TSP1 and VEGF on T cell activation, and reveals an important role for CD47 signaling in regulating T cell production of the major angiogenic factor VEGF.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25200950      PMCID: PMC4185246          DOI: 10.4049/jimmunol.1303116

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A.

Authors:  Partha Pratim Manna; William A Frazier
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

2.  Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion.

Authors:  Heba O Barazi; Zhuqing Li; Jo Anne Cashel; Henry C Krutzsch; Douglas S Annis; Deane F Mosher; David D Roberts
Journal:  J Biol Chem       Date:  2002-09-05       Impact factor: 5.157

Review 3.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Authors:  Harold F Dvorak
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

4.  Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation.

Authors:  Z Li; L He; K Wilson; D Roberts
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

5.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Authors:  D I Gabrilovich; T Ishida; S Nadaf; J E Ohm; D P Carbone
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

6.  Distinct requirements for C-C chemokine and IL-2 production by naive, previously activated, and anergic T cells.

Authors:  C G Lerner; M R Horton; R H Schwartz; J D Powell
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

7.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 8.  Tumorigenesis and the angiogenic switch.

Authors:  Gabriele Bergers; Laura E Benjamin
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

Review 9.  Immature myeloid cells and cancer-associated immune suppression.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2002-04-24       Impact factor: 6.968

10.  Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior.

Authors:  Zhuqing Li; Maria J Calzada; John M Sipes; Jo Anne Cashel; Henry C Krutzsch; Douglas S Annis; Deane F Mosher; David D Roberts
Journal:  J Cell Biol       Date:  2002-04-29       Impact factor: 10.539

View more
  45 in total

Review 1.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

2.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

3.  Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.

Authors:  Pulak Ranjan Nath; Dipasmita Pal-Nath; Ajeet Mandal; Margaret C Cam; Anthony L Schwartz; David D Roberts
Journal:  Cancer Immunol Res       Date:  2019-07-30       Impact factor: 11.151

4.  A function-blocking CD47 antibody modulates extracellular vesicle-mediated intercellular signaling between breast carcinoma cells and endothelial cells.

Authors:  Sukhbir Kaur; Abdel G Elkahloun; Satya P Singh; Anush Arakelyan; David D Roberts
Journal:  J Cell Commun Signal       Date:  2017-11-29       Impact factor: 5.782

5.  Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells.

Authors:  Patrick Coit; Paul Renauer; Matlock A Jeffries; Joan T Merrill; W Joseph McCune; Kathleen Maksimowicz-McKinnon; Amr H Sawalha
Journal:  J Autoimmun       Date:  2015-05-23       Impact factor: 7.094

6.  VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.

Authors:  Oisun Jung; DeannaLee M Beauvais; Kristin M Adams; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2019-10-28       Impact factor: 5.285

7.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Authors:  David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

8.  Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Authors:  Teresa Di Desidero; Lisa Derosa; Luca Galli; Paola Orlandi; Andrea Fontana; Anna Fioravanti; Riccardo Marconcini; Mario Giorgi; Beatrice Campi; Alessandro Saba; Sara Lucchesi; Renato Felipetto; Romano Danesi; Giulio Francia; Giacomo Allegrini; Alfredo Falcone; Guido Bocci
Journal:  Invest New Drugs       Date:  2016-08-24       Impact factor: 3.850

Review 9.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

Review 10.  Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.

Authors:  Xi Zhang; Yuge Ran; Yongjie Shao; Kunjie Wang; Yuanxue Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.